PYLARIFY PET-CT scan to find spread in certain cancers
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Skin clinical trials.
This early study tests whether a special PET-CT scan called PYLARIFY can detect metastasis (cancer spread) more effectively in pancreatic, liver (HCC), and breast cancers. If the scan results change doctors’ treatment plans, it could help you get the right next therapy sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You should be well enough to do daily activities (performance status score of 2 or less).
- You must have one of these confirmed cancers: pancreatic ductal adenocarcinoma, hepatocellular carcinoma, or invasive lobular breast cancer.
- You need signs of possible spread or known spread, and you must have at least one “measurable” spot on standard scans that doctors can accurately track.
- You must be willing to undergo a biopsy if needed to confirm the scan results.
- You cannot be pregnant or breastfeeding during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special PET scan (18F-FSPG) to help guide therapy for people with liver cancer (HCC) who are planning to receive Y90 radioembolization. The scan may help doctors better plan your treatment.
This trial tests a new imaging agent (18F-FAPI) to see if it can help find tumors early in people with lung, thyroid, pancreatic, melanoma, or neuroendocrine cancers.
This trial uses a special imaging scan called FAPI-PET to help doctors better diagnose pancreatic cancer. If you are suspected of having pancreatic cancer or a recurrence, this study may help confirm or clarify your diagnosis.
This trial tests a new PET scan (called FFNP) to see if it can find which breast cancers stop responding to hormone therapy early. It's for people with advanced hormone-receptor-positive breast cancer who are starting a new endocrine treatment.
This observational study follows men with prostate cancer who get a specific PET scan (PYLARIFY) to see how well it identifies cancer spread or recurrence. It may help doctors better understand where the cancer is so treatment decisions can be improved.
This trial tests a new PET scan tracer that targets a protein found on certain cancer cells. It may help doctors better see and understand tumors in people with colorectal, gastric, pancreatic, lobular breast, or ovarian cancer.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.